Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.92
+3.63 (1.42%)
AAPL  336.67
+3.04 (0.91%)
AMD  645.86
-3.56 (-0.55%)
BAC  53.52
-0.57 (-1.05%)
GOOG  347.37
+2.78 (0.81%)
META  721.31
-17.57 (-2.38%)
MSFT  529.76
+0.46 (0.09%)
NVDA  237.47
-1.77 (-0.74%)
ORCL  143.56
-1.21 (-0.84%)
TSLA  377.81
-2.87 (-0.75%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.